Genentech, a member of Roche Group, has obtained clearance for its Lucentis 0.3 mg (ranibizumab injection) from the US Food and Drug Administration (FDA). Lucentis 0.3 mg is a recombinant humanized monoclonal antibody fragment (lacking an ...
Tags: Genentech, Lucentis 0.3 mg, Medicine, Injection
The US Food and Drug Administration (FDA) has approved Genentech's Perjeta (pertuzumab) for the treatment of HER2-positive metastatic breast cancer (mBC), in combination with Herceptin (trastuzumab) and docetaxel chemotherapy. The ...
Tags: FDA approval, breast cancer, clinical study, pharmaceutical product